RBC Capital lowers Johnson & Johnson stock price target on valuation
RBC Capital cut its price target for Johnson & Johnson (JNJ) to $280 from $290, citing valuation and recent stock decline. JNJ reported Q3 2026 earnings of $2.59 per share, beating estimates, with revenue at $25.4B. The stock fell 6% due to litigation charges, margin pressures, and MedTech underperformance.
How this was made
The 30-second read
Why it matters
The price‑target reduction reflects a reassessment of near‑term upside, potentially prompting short‑term selling.
Market read
Analyst downgrade on a large‑cap healthcare name provides a fresh catalyst for traders; the news is material and actionable today.
What to watch
The litigation charge is a one‑time item; cash flow remains robust, and the dividend yield remains attractive.
Background
RBC Capital's analyst Trung Huynh noted a 6% share decline despite in‑line Q3 results, citing a talc litigation charge and MedTech margin pressure.
Ticker impact
RBC Capital lowered its price target on Johnson & Johnson to $280 from $290 and reported Q3 2026 earnings of $2.59 EPS and $25.4B revenue.
likely pressure as the market prices in the target reduction and litigation risk
The new target is a concrete, time‑sensitive catalyst; combined with a notable talc litigation charge, it outweighs the modest earnings beat.
Market effects
Other pharma stocks may face heightened scrutiny as the target cut signals valuation pressure in the sector.
U.S. equities, especially healthcare, could see modest downside.
Limited; impact confined to U.S. and large‑cap healthcare investors.
Counterpoint
Despite the target cut, JNJ's strong fundamentals and defensive positioning could make it a buy on dip.
Key entities
- companyJohnson & Johnson
U.S. healthcare conglomerate reporting Q3 2026 results.
- analyst_firmRBC Capital
Equity research house that lowered JNJ's price target.
